ClinicalTrials.gg
Not yet recruitingNCT05876832Updated May 26, 2023

A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE)

A Phase 3 interventional study of XY0206 and Salvage Chemotherapy in Acute Myeloid Leukemia With FLT3/ITD Mutation, sponsored by Shijiazhuang Yiling Pharmaceutical Co. Ltd. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-26.

Sponsored by Shijiazhuang Yiling Pharmaceutical Co. Ltd · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
312
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to determine the clinical benefit of XY0206 therapy in participants with FLT3-ITD mutated AML who are refractory to or have relapsed after prior AML therapy as shown with overall survival (OS) compared to salvage chemotherapy. In addition, this study is also to investigate the efficacy of XY0206 as assessed by CR/CRh rate in these subjects。

Read the detailed description

Participants considered an adult according to local regulations at the time of signing informed consent will be randomized in a 2:1 ratio to receive XY0206 or salvage chemotherapy. Participants will enter the screening period up to 14 days prior to the start of treatment. Prior to randomization, the investigator will preselect a salvage chemotherapy regimen for each participant; options will include low-dose cytarabine (LoDAC),azacitidine, fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG) or mitoxantrone, etoposide and cytarabine (MEC) . The randomization will be stratified by remission from previous treatment and preselected salvage chemotherapy. Participants will be administered treatment over continuous 28-day cycles.

Participants who have a donor identified and with complete remission after treatment may undergo hematopoietic stem cell transplant (HSCT) without leaving the study.

After treatment discontinuation, participants will have a end-of-treatment visit within 7 days after treatment discontinuation, followed by a 30-day follow-up for safety. After that, long term follow-up will be done every 90 days.

02

Conditions studied

  • Acute Myeloid Leukemia With FLT3/ITD Mutation
03

In context

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

This study's planned enrollment of 312 is above the median of 40 across 3,007 interventional studies indexed under Leukemia, Myeloid, Acute.

Browse Leukemia, Myeloid, Acute studies →

Lead sponsor

Shijiazhuang Yiling Pharmaceutical Co. Ltd is the lead sponsor of 13 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age≥18 years old.
  2. Subject has a diagnosis of primary AML or AML secondary to myelodysplastic syndrome (MDS) according to World Health Organization (WHO) classification as determined by pathology review at the treating institution.
  3. Subject is to or relapsed after prior AML therapy (with or without hematopoietic stem cell transplant ):

    • Advanced relapse after AML therapy is defined as: the patients achieved Complete remission without minor residual diseases/complete remission/complete remission with partial hematologic recovery/complete remission with incomplete hematologic recovery/complete remission with incomplete recovery/Morphologic leukemia- free state(CRMRD-/CR/CRh/CRi/CRp/MLFS )after first-line treatment and relapsed after 12 months with hematological relapse;
    • Patients with relapsed / refractory AML.
    • Refractory to first-line AML therapy is defined as:the patient did not achieve CRMRD-/CR/CRh/CRi/CRp/MLFS under initial therapy.A subject eligible for standard therapy must receive at least 1 cycle of an anthracycline containing induction block in standard dose for the selected induction regimen. A subject not eligible for standard therapy must have received at least 1 complete block of induction therapy seen as the optimum choice of therapy to induce remission for this subject.
    • Early relapse:Relapse within 12 months after consolidation therapy after achieving CRMRD-/CR/CRh/CRi/CRp/MLFS.
    • Relapse after 12 months but nonresponse to conventional chemotherapy after achieving CRMRD-/CR/CRh/CRi/CRp/MLFS.
    • Second or more relapse.
    • Patients who cannot tolerate intensive chemotherapy develop disease progression during continuous treatment with low-intensity drugs.
    • Persistence of extramedullary leukemia.
  4. Patient is positive for FLT3-ITD mutation in bone marrow or whole blood.
  5. (ECOG) performance status ≤ 2.
  6. Expected survival ≥12 weeks .
  7. Patient must meet the following criteria as indicated on the clinical laboratory tests:

    • Serum creatinine ≤ 1.5 x or an estimated of ≥50 mL/min .
    • Serum (AST) and alanine aminotransferase (ALT) ≤ 2.5 x upper limit of normal (ULN)
    • Serum total (TBL) ≤ 1.5 x ULN.
    • Fridericia's Heart Rate Correction Formula () interval ≤480 msec.
  8. Female patients of must have a negative serum pregnancy test within 14 days prior to the first study drug administration.Female patients of childbearing potential and male must be surgically sterile or willing to use highly effective upon enrollment, during the treatment period, and for 6 months following the last dose of drug.
  9. The subject should be willing to provide evidence of valid diagnosis before treatment or undergo bone marrow puncture or for diagnosis, and receive bone marrow puncture or biopsy for efficacy evaluation after treatment.
  10. Patients volunteered to participate in this study and signed the form.

Exclusion criteria

Exclusion Criteria:

  1. Patient was diagnosed as acute promyelocytic leukemia (APL), or Philadelphia chromosome(BCR-ABL)-positive leukemia (chronic myelogenous leukemia in blast crisis).
  2. Patients who received (including live attenuated vaccine) within 4 weeks before randomization and/or planed to receive live vaccine after enrollment.
  3. Presence of FLT3-tyrosine kinase domain(TKD) mutation.
  4. Patients were prior failed adequate treatment with FLT3 inhibitors.
  5. AML with Central Nervous System Leukemia.
  6. Patient has AML secondary to prior chemotherapy for other neoplasms, except for MDS.
  7. Patients with other malignant tumors past or present,unless whose Disease-free survival period≥5 years.Non-melanin skin cancer, carcinoma in situ, or cervical intraepithelial neoplastic lesions with completed radical treatment (regardless of disease-free survival),and subjects with prostate cancer confined to the prostate and with no evidence of disease recurrence or progression,if they have started hormonal therapy or have undergone surgery to remove the or have undergone radical radiotherapy,will be eligible for the study.
  8. Pretrial treatment conditions:

    • Patients who received hematopoietic stem cell transplantation within the 2 months before enrollment,or having (GVHD) or receiving systemic cortisol hormone therapy for GVHD.
    • Patients who received chemotherapy, biological therapy, targeted anti-tumor therapy within 14 days before the first use of the drug in this study or within 5 half-lives of the drug, or radiation therapy within 28 days.
    • Patients who participated in other clinical trials and received trial drugs within 28 days to the first study dose.
    • Patients who have had major surgery or significant traumatic injury within 28 days to the first study dose or planted to require major surgery during study treatment.
  9. Concurrent disease conditions:

    • Patients are surface antigen or core antibody actives positive,and hepatitis B virus(HBV) DNA ≥2000IU/mL or 1×104 copy/mL.
    • Patients are virus (HCV) antibody actives positive and HCV-RNA quantification is above the at each center.
    • (HIV) seropositivity.
    • Patient has clinically obvious gastrointestinal abnormalities that may affect the intake, transport, or absorption of drugs (such as inability to swallow, chronic diarrhea, intestinal obstruction, etc),patients with total gastrectomy or major gastrectomy (Billroth II), patients with a clear gastrointestinal bleeding tendency,or major gastrointestinal bleeding considered possible by the investigator.
    • Patient has uncontrolled epilepsy history.
    • Patient has uncontrolled hypertension defined as systolic blood pressure greater than 160 mmHg or diastolic pressure greater than 100 mmHg, despite optimal medical management and optimal measurement.
    • Patient has clinically significant abnormal serum lipase or amylase indicators during screening.
    • Patient has intractable hypokalemia or hypomagnesemia.
    • Patient has clinically significant abnormality of coagulation profile, such as disseminated intravascular coagulation (DIC), hemophilia.
    • Patient has congestive heart failure (NYHA) class 3 or 4 or patient with a history of congestive heart failure NYHA class 3 or 4 in the past, unless a screening echocardiogram performed within 1 month before study entry results in a that is ≥ 45%.
    • Patients with second degree (Mobitz II) or third degree atrioventricular block disease (except for patients who use the pacemaker) or complete left bundle branch block.
    • Patients with new clinically significant arrhythmias (except for sinus tachycardia caused by anemia, infection and AML) or patients with previous arrhythmias that require long-term use of drugs with -prolonging effects.
    • Patients with any one of the following diseases within 6 months prior to randomization:myocardial infarction,unstable angina pectoris,Patients undergoing coronary artery bypass graft(CABG) or peripheral artery bypass implantation,congestive heart-failure,Cerebrovascular events (including cerebral hemorrhage and cerebral infarction, etc.),Deep venous thrombosis (except for deep venous thrombosis due to peripherally inserted central venous catheter (PICC) catheterization),pulmonary embolism and other diseases that the researcher considers inappropriate to participate in this study.
    • Patients with diagnosed or suspected long QT syndrome at screening (including a family history of long QT syndrome).
    • Patient has an active uncontrolled infection.
    • Patient has severe unhealed wounds, ulcers, or fractures.
    • Females who are pregnant or breastfeeding.
    • Patients are not suitable for the study in the investigator's opinion.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
312 participants (estimated)

Study arms

  • Experimental
    XY0206

    XY0206 will be administered orally once a day in continuous 28-day cycles.

    Drug: XY0206

  • Active comparator
    Salvage chemotherapy

    Participants will receive salvage chemotherapy in 28-day cycles. Participants on Low-Dose Cytarabine (LoDAC) received 20 mg of cytarabine twice daily by subcutaneous (SC) injection for 10 days. Participants on azacitidine will receive 75 mg/m\^2 daily by SC or IV injection for 7 days.Participants on fludarabine, cytarabine and granulocyte colony-stimulating factor (G-CSF) (FLAG) will receive 30 mg/m\^2 of fludarabine daily by IV for 5 days (day 2 to 6), 1\~2 g/m2 of cytarabine daily by IV for 5 days (day 2 to 6), and 300 μg/m\^2 of G-CSF daily by SC or IV for 5 days (days 1 to 5). After completion of chemotherapy, G-CSF will be administered continually until absolute neutrophil count(ANC)\>0.5 x 10\^9 / L. Participants on mitoxantrone, etoposide, cytarabine(MEC) will receive 8 mg/m\^2 of mitoxantrone daily by IV for 3 days (day 1 to 3), 100 mg/m2 of etoposide daily by IV for 7 days (day 1 to 7), and 100 mg/m\^2 of cytarabine daily by IV for 7 days (days 1 to 7)

    Drug: Salvage Chemotherapy

Interventions

  • DrugXY0206

    Dosage form:Tablet;Multiple dose phase:Take the medicine once a day,37.5mg at a time.4 weeks of continuous medication is one course of treatment. After the first course of treatment, the subjects can continue to receive the experimental drug treatment until the subjects meet the withdrawal criteria.

  • DrugSalvage Chemotherapy

    Low-dose Cytarabine (LoDAC) or azacitidine, fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG) or mitoxantrone, etoposide, cytarabine (MEC)will be administered by subcutaneous (SC) and/or intravenous (IV) injections.

06

What researchers measure

Primary outcomes

  1. Interim analysis: Complete remission(CR)/CR with partial hematologic recovery(CRh) rate in the experimental group.

    The complete remission and complete remission with partial hematological recovery (CR/CRh) rate was defined as the number of subjects who achieved either CR or CRh at any of the postbaseline visits divided by the number of subjects in the analysis population.

    Time frame: up to 3 years.

  2. The final analysis: Overall Survival(OS).

    Overall survival was defined as the time from the date of randomization until the date of death from any cause.

    Time frame: up to 3 years .

Secondary outcomes

  1. Key secondary end point: Event-Free Survival (EFS).

    Event-free survival (EFS) is defined as the time from the date of randomization until the date of documented relapse, treatment failure or death whichever occurs first.

    Time frame: up to 3 years.

  2. Key secondary end point: CR/CRh rate .

    The CR/CRh rate was defined as the number of subjects who achieved either CR or CRh at any of the postbaseline visits divided by the number of subjects in the analysis population.

    Time frame: up to 3 years.

  3. CR rate.

    The CR rate was defined as the number of subjects who achieved the best response of CR divided by the number of subjects in the analysis population.

    Time frame: up to 3 years.

  4. Duration of remission (DOR).

    Duration of remission included duration of composite complete remission (CRc), duration of complete remission (CR)/ complete remission with partial hematologic recovery (CRh), duration of CRh, duration of CR and duration of response (CRc + partial remission (PR).

    Time frame: up to 3 years.

  5. Composite complete remission rate.

    CRc rate is defined as the remission rate of all CR, CRh , CR with incomplete hematologic recovery(CRi) or Morphologic leukemia- free state(MLFS).

    Time frame: up to 3 years.

  6. minimal residual disease(MRD) negative rate

    MRD negative rate is defined as the percentage of participants without MRD.

    Time frame: up to 3 years.

  7. Time to remission(TTR).

    Time to remission(TTR) is defined as the time from the date of randomization until the date of is defined as the time from the date of randomization until the date of remission.

    Time frame: up to 3 years.

  8. Transplantation rate.

    Transplantation rate is defined as the percentage of participants undergoing hematopoietic stem cell transplant (HSCT).

    Time frame: up to 3 years.

  9. Safety assessed by adverse events.

    An adverse event (AE) is defined as any untoward medical occurrence in a participant administered a study drug or has undergone study procedures and which does not necessarily have a causal relationship with this treatment.

    Time frame: up to 3 years.

  10. Population pharmacokinetic of XY0206.

    Observed trough concentration (Ctrough).

    Time frame: Cycle 1 Day 15: predose and up to 4 hours post-dose; Day 28 predose of subsequent cycles. A cycle is 28 days.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2023; primary completion for Jul 2027, 48 months later.

Of 43 industry-sponsored phase 3 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 62. This study's planned 48 months is above that.

Counting every sponsor, half of 121 studies reached it within 74 months; a quarter within 39 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2023
First posted
May 25, 2023
StartEst.
Jun 15, 2023
Primary completionEst.
Jul 1, 2027
CompletionEst.
Jul 1, 2027
Last update
May 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05876832
Lead sponsor
Shijiazhuang Yiling Pharmaceutical Co. Ltd
Responsible party
Sponsor
First posted
May 25, 2023
Start date
Jun 15, 2023 (estimated)
Primary completion
Jul 1, 2027 (estimated)
Completion
Jul 1, 2027 (estimated)
Last update
May 26, 2023

Study contacts

Wang wei, master
Contact
wangwei001@yiling.cn
086-0311-66703017
Jianxiang Wang, MD
Contact
wangjx@ihcams.ac.cn
022-23909120

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: FLT3 Inhibitor XY0206

Start the discussion